Effect of hormone modulation therapy on bone tissue in the treatment of endometriosis

Maria A. Shalina, Maria I. Yarmolinskaya, Elena V. Misharina
In: Journal of obstetrics and women's diseases · 2018 · vol. 67(5) , pp. 50–55 · doi:10.17816/jowd67550-55 · W2904813332
article OA: hybrid CC0 ⤵ 1 in-corpus citation
🔓 Open OA copy View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This review discusses how hormone modulation therapies like GnRH agonists, aromatase inhibitors, and dienogest affect bone mineral density in patients treated for endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-10 ⓘ

This paper is a literature review on how hormone modulation therapies used for external genital endometriosis—gonadotropin-releasing hormone agonists, aromatase inhibitors, and dienogest 2 mg—affect bone mineral density, focusing on proposed mechanisms and results from domestic and international studies. It reports that long-term gonadotropin-releasing hormone agonist use can reduce bone mineral density and shift remodeling toward resorption, with potential mitigation strategies discussed such as add-back approaches and calcium/vitamin D3 (and, when needed, antiresorptive therapy), while aromatase inhibitors are described as generally increasing fracture risk and lowering bone mineral density to varying degrees, depending on agent and baseline bone status. For dienogest, the review motivates evaluation based on negative bone effects attributed to depot medroxyprogesterone acetate and describes dienogest’s progestagenic actions and rationale for long-term use, but the provided text does not yet detail its bone-specific outcomes. The paper does not explicitly list formal limitations of the review in the excerpt, but it relies on synthesis of heterogeneous prior studies and emphasizes the need for bone monitoring. This paper is centrally about endometriosis — it specifically reviews hormone-modulating treatments for external genital endometriosis and their impacts on bone mineral density.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

This article presents a review of the current literature on the impact of such drugs as gonadotropin-releasing hormone agonists, aromatase inhibitors, and dienogest 2 mg, which are used for the treatment of external genital endometriosis, on the mineral density state. In the paper, we discuss the pathogenetic mechanisms of the effects of various bioactive compounds on bone and the results of domestic and foreign research.

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (16)

Cited by (1)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK